En décembre 2023, LNE-GMED UK, filiale GMED du groupe LNE a été accrédité par UKAS (United Kingdom Accreditation Service) au titre de la norme...

UK – GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia

The agency’s final draft guidance applies to both newly diagnosed and previously treated patients, although those eligible will need to have either not been...

Europe – Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 September 2023

New safety information for Omega-3-acid ethyl esters The PRAC agreed to add atrial fibrillation (irregular, rapid contraction of the heart) as a common side effect to the product...

France – Martine Wonner suspendue pour un an par l’ordre des médecins

La chambre disciplinaire du conseil régional de l’ordre des médecins du Grand-Est a annoncé, vendredi 25 novembre, la suspension pour un an des activités médicales...

UK – ICR calls for further discussions following NICE’s rejection of breast cancer drug

Olaparib – a drug developed through UK-led and funded science – has been shown to cut the risk of cancer recurrence and improve survival...

Europe – IA: la Commission européenne renforce l’exigence de garantie humaine

PARIS (TICpharma) - Le futur règlement européen sur l'intelligence artificielle (IA) devrait être finalisé "début 2023", signant le "top chrono" pour la mise en...
NICE ‘OK’ for Lynparza

UK – NICE recommends Janssen’s treatment for active psoriatic arthritis

Tremfya – also known as guselkumab – has been recommended by the National Institute for Health and Care Excellence (NICE) for people with active...